CN Patent

CN104203266B — Glp‑1肽组合物及其制备

Assigned to Novo Nordisk AS · Expires 2017-12-26 · 8y expired

What this patent protects

本发明涉及包含第一类型颗粒和第二类型颗粒的药物组合物，其中所述第一类型颗粒包含N‑(8‑(2‑羟基苯甲酰)氨基)辛酸盐且不含GLP‑1肽，且其中所述第二类型颗粒包含GLP‑1肽且不含N‑(8‑(2‑羟基苯甲酰)氨基)辛酸盐，以及中间体颗粒，用于制备所述颗粒和组合物的方法，及其在医药中的用途。

USPTO Abstract

本发明涉及包含第一类型颗粒和第二类型颗粒的药物组合物，其中所述第一类型颗粒包含N‑(8‑(2‑羟基苯甲酰)氨基)辛酸盐且不含GLP‑1肽，且其中所述第二类型颗粒包含GLP‑1肽且不含N‑(8‑(2‑羟基苯甲酰)氨基)辛酸盐，以及中间体颗粒，用于制备所述颗粒和组合物的方法，及其在医药中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN104203266B
Jurisdiction
CN
Classification
—
Expires
2017-12-26
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.